Acetylon Pharmaceuticals Receives $14,600,000 Series B Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b0f2ed69-9501-4125-bfb5-5f8063b45d5c&Preview=1 - Date
6/29/2011 - Company Name
Acetylon Pharmaceuticals - Mailing Address
303 Congress Street 2nd Fl Boston, MA 02210 - Company Description
Acetylon Pharmaceuticals is a Boston-based company recently formed to commercialize promising pharmaceutical technology emerging from collaborative research at Harvard University and the Dana-Farber Cancer Institute. Acetylon intends to pursue the clinical development and commercialization of next generation, selective, small-molecule Histone Deacetylase (HDAC) inhibitors with enhanced therapeutic effectiveness and tolerability versus current alternatives. - Website
http://www.acetylon.com - Transaction Type
Venture Equity - Transaction Amount
$14,600,000 - Transaction Round
Series B - Proceeds Purposes
The proceeds will be used in part to fund the advancement of the Company’s lead drug candidate ACY-1215 – a next-generation Class II-selective histone deacetylase (HDAC) inhibitor – into Phase I/II clinical testing for patients with relapsed and relapsed-refractory multiple myeloma. This funding is part of a $27 million series B financing round. - M&A Terms
- Venture Investor
Undisclosed
